Clinical Observation of Nape Acupuncture plus Rehabilitation Training in Treating Pseudobulbar Palsy After Cerebral Stroke
10.13460/j.issn.1005-0957.2018.02.0135
- VernacularTitle:"项针"联合康复训练治疗脑卒中后假性球麻痹临床观察
- Author:
Fei-Yu CHEN
1
;
Xiao-Ping LIU
;
Ye-Hua BAO
;
Jia-Mei CHU
Author Information
1. 杭州市丁桥医院
- Keywords:
Acupuncture;
Stroke complications;
Deglutition disorders;
Pseudobulbar palsy;
Points;
Head & Neck;
Nape acupuncture therapy;
Rehabilitation;
Age of onset
- From:
Shanghai Journal of Acupuncture and Moxibustion
2018;37(2):135-139
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of nape acupuncture plus basic treatment and rehabilitation in treating pseudobulbar palsy after cerebral stroke and the relation between the efficacy and age of onset. Method A hundred patients were randomized into an observation group and a control group, 50 cases each. The control group was intervened by basic treatment and swallowing rehabilitation training, and the observation group was intervened by nape acupuncture in addition to the treatment given to the control group, once a day, five sessions a week, for 8 weeks in total. The Repetitive Saliva Swallowing Test (RSST), Water Swallowing Test (WST) and Standardized Swallowing Assessment (SSA) were observed in the two groups before and after the treatment; the relation between the age of onset and the efficacy of the integrated treatment method was also observed. Result The scores of RSST, SSA and WST were significantly improved after the treatment in both groups (P<0.01), and the improvements in the observation group were more significant than those in the control group (P<0.01). The therapeutic efficacy of nape acupuncture plus basic treatment and swallowing rehabilitation training was associated with the age of onset (P<0.05). Conclusion Nape acupuncture plus basic treatment and swallowing training can effectively improve dysphagia in pseudobulbar palsy after cerebral stroke. This method produces the most significant efficacy for patients aged 51-60, better than that for those aged over 60 and equivalent to the efficacy for patients aged 41-50.
